Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
RDRedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. (RDHL)

NASDAQ Global Market · Currency in USD
$0.42 ▲ +0.00 (+0.26%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.42 ▼ -0.01 (-1.91%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$0.42
Open
$0.41
Day's Range
$0.41 – $0.45
52 Week Range
$0.41 – $1.67
Volume
108,144
Avg. Volume
1,500,351
Market Cap
$1.33M
Beta (5Y Monthly)
4.90
PE Ratio (TTM)
--
EPS (TTM)
-$0.14
Earnings Date
Mar 18, 2027
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: RedHill Biopharma Ltd.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
13
CEO
Dror Ben-Asher

RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds.

Earnings

Next report: Thu, Mar 18, 2027
EPS estimate -$474.29 · Revenue est. $24.51M
DateEst.Actual
Sep 5, 2025-$690.00-$1.00Beat
Apr 10, 2025-$690.00-$1.00Beat
Oct 3, 2024-$690.00-$1.00Beat
Jul 30, 2024-$0.30-$2.00Miss
Apr 8, 2024–-$1.00
Mar 14, 2024-$0.03-$0.20Miss

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on RDHL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.